Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Viridian Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 33 | 26 | −7 |
| Shares | 5.54M | 6.00M | +460.2K (+8.3%) |
| Value | $84.5M | $109.8M | +$25.3M (+29.9%) |
New holders (4)
Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Perceptive Advisors LLC | 794,506 | $14.5M | 0.19% |
| Northern Trust Corp | 31,467 | $576.0K | 0.00% |
| State Street Corp | 11,041 | $202.0K | 0.00% |
| Morgan Stanley | 6,985 | $128.0K | 0.00% |
Sold out (11)
Institutions that held Viridian Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Logos Global Management LP | 550,000 | $9.19M |
| Soleus Capital Management, L.P. | 67,685 | $1.13M |
| Driehaus Capital Management LLC | 33,333 | $557.0K |
| Maven Securities LTD | 27,898 | $470.0K |
| Renaissance Technologies LLC | 13,240 | $221.0K |
| Squarepoint Ops LLC | 11,668 | $195.0K |
| Citadel Advisors LLC | 485,995 | $44.0K |
| Advisor Group Holdings, Inc. | 950 | $16.0K |
| Tower Research Capital LLC (TRC) | 118 | $2.00K |
| JPMorgan Chase & Co | 10 | $0 |
| Bank of America Corp | 16 | $0 |